Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Oragenics Inc (OGEN)

Oragenics Inc (OGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,876
  • Shares Outstanding, K 46,125
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,910 K
  • 60-Month Beta 1.70
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.76
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.29
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 04/03/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.10
  • Number of Estimates 2
  • High Estimate -0.09
  • Low Estimate -0.10
  • Prior Year -0.09
  • Growth Rate Est. (year over year) -11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.42 +34.10%
on 01/30/20
0.77 -26.82%
on 02/10/20
+0.10 (+21.94%)
since 01/17/20
3-Month
0.42 +34.10%
on 01/30/20
0.77 -26.82%
on 02/10/20
+0.07 (+15.00%)
since 11/20/19
52-Week
0.35 +61.00%
on 08/15/19
0.99 -43.08%
on 03/18/19
-0.34 (-37.39%)
since 02/20/19

Most Recent Stories

More News
Oragenics, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of effective treatments for oral mucositis and new antibiotics against infectious diseases, announced today that Alan Joslyn, Ph.D., president...

OGEN : 0.56 (unch)
Oragenics Inc. to Present at the LD Micro 12th Annual Main Event on December 10, 2019

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced that Alan Joslyn, Ph.D., president...

OGEN : 0.56 (unch)
Oragenics, Inc. Announces Completion of Enrollment of Its Phase 2 Clinical Trial for AG013 in Oral Mucositis

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced the completion of enrollment...

OGEN : 0.56 (unch)
XON : 4.65 (-4.12%)
Oragenics, Inc. Publishes Peer-Reviewed Study in Journal of Peptide Science Demonstrating First Complete Chemical Synthesis of Bicyclic Ring of a Mutacin 1140 Analog

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis ("OM"), today announces the publication of...

OGEN : 0.56 (unch)
Oragenics, Inc. SVP of Discovery Research, Martin Handfield, Ph.D. to Be Featured Speaker at the International Conference on Microbial Research and Applications

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announces the company's Senior Vice...

OGEN : 0.56 (unch)
Oragenics, Inc. to Present at the BIO Investor Forum

Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced it will be presenting...

OGEN : 0.56 (unch)
XON : 4.65 (-4.12%)
Oragenics Presents Interim Data on The AG013 Phase 2 Clinical Trial at the European Society for Medical Oncology Congress 2019

Oragenics, Inc. (NYSE American:OGEN) ("Oragenics"), a leader in the development of novel antibiotics against infectious diseases and effective treatments for oral mucositis, today announces initial data...

OGEN : 0.56 (unch)
XON : 4.65 (-4.12%)
Oragenics, Inc. Announces Phase 2 Clinical Trial of AG013 Reaches Enrollment of 158 Patients

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announces it has enrolled 158 patients...

OGEN : 0.56 (unch)
XON : 4.65 (-4.12%)
Oragenics, Inc. to Present Interim Data on AG013 at the European Society of Medical Oncology Congress

Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis ("OM"), today announces that an abstract from...

OGEN : 0.56 (unch)
Oragenics Inc. to Present September 10 at the 21st Annual Rodman and Renshaw Global Investment Conference

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis ("OM"), today announced that Alan Joslyn, president...

OGEN : 0.56 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade OGEN with:

Business Summary

Oragenics Inc is a biotechnology company focused on the development and licensure of innovative products and technologies for improving human health.

See More

Key Turning Points

2nd Resistance Point 0.61
1st Resistance Point 0.59
Last Price 0.56
1st Support Level 0.54
2nd Support Level 0.52

See More

52-Week High 0.99
Fibonacci 61.8% 0.75
Fibonacci 50% 0.67
Fibonacci 38.2% 0.59
Last Price 0.56
52-Week Low 0.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar